Indications and Safety of Rituximab in Pediatric Neurology: A 10-Year Retrospective Study

AT, Nguyen; C, Cotteret; Durrleman, C; Barnérias, Christine; Hully, Marie; Gitiaux, Cyril; Mesples, B; Bustamante, Jorge Luis; Chhun, S; Fayard, C; Cisternino, S; JM, Treluyer; Desguerre, Isabelle; Aubart, Mélodie

doi:10.1016/j.pediatrneurol.2022.08.004

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some children respond to repeat induction therapy, particularly with steroids and rituximab, 7–9 but prolonged treatment courses with corticosteroids place children at risk of toxicities including infection, osteopenia, and metabolic syndrome. Additionally, rituximab may cause infusion toxicity and sustained susceptibility to infections 10 . Studies that evaluated alternative immunosuppressants in relapsed/refractory NBL‐associated OMAS showed no durable benefit, though those approaches primarily acted through lymphocyte or antibody depletion 11–13 .…”

Section: Introductionmentioning

confidence: 99%

Successful use of tacrolimus for treatment‐refractory neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia syndrome: A case series

Delap,

Shah,

Kuns

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Opsoclonus‐myoclonus‐ataxia syndrome (OMAS) is an autoimmune central nervous system disorder, primarily manifesting as a paraneoplastic sequalae to neuroblastoma, and characterized by motor disorders and behavioral disturbances. OMAS is typified by aberrant B‐cell and T‐cell activation. Current treatment involves immunosuppression using corticosteroids, intravenous immunoglobulin, and rituximab. However, these approaches often lead to treatment‐related toxicities and symptomatic recurrences with chronic neurocognitive impairment. We treated three children with refractory neuroblastoma‐associated OMAS with tacrolimus, a T‐cell‐targeting calcineurin inhibitor, effectively controlling symptoms within a month and enabling the discontinuation of immunosuppression with minimal side effects. Tacrolimus shows promise as a therapeutic option for refractory OMAS.

show abstract

Section: Introductionmentioning

confidence: 99%